Welcome

This Annual Report of the European College of Neuropsychopharmacology (ECNP) presents the numerous activities carried out in 2012 and explains how these activities have contributed to the fulfilment of ECNP’s mission:

“To advance the science of the brain, promote better treatment and enhance brain health”.

2012 was a most notable event as we celebrated the 25th anniversary of ECNP. In these 25 years ECNP has played a major role in the evolution of neuropsychopharmacology.

The characteristics that have defined ECNP for 25 years – its focus on high-quality research and education; excellent organisation; constructive, but independent engagement with industry; close cooperation with national European and international organisations – continue to shape its strategic direction and guide its future. The organisation is at the top of the tree in terms of both people and delivery and it has the highest integrity.

I am humbled by the dedicated volunteers, passionate members and supporters and committed staff who have invested and continue to invest their precious time. Your collective efforts continue to fuel our enthusiasm and motivation to fulfil ECNP’s mission.

Joseph Zohar
President ECNP
In March 1984, representatives of neuropsychopharmaceutical societies from across Europe sat down to dinner in Copenhagen to mark the 25th anniversary of the then Scandinavian Association of Psychopharmacology. European integration was in the air. The question was raised: might there be a case for a European structure, to give European neuropsychopharmacologists a platform to exchange and promote the region’s best research?

To follow-up on this idea, a meeting was held in Copenhagen in 1985. The rationale of a pan-European organisation was so powerful that it was decided to take it further: a European College of Neuropsychopharmacology (ECNP) would be founded. A Working Group was formed to plan the association’s inaugural scientific congress.

The inaugural congress was held in Brussels in 1987. Some 500 people attended from across Europe. ECNP was formally launched. The College’s constitution came two years later in Gothenburg—the same governance structure that serves ECNP today.

As well as the Congress, the College started a wide range of meetings, educational activities and scientific programmes. Together, these activities and initiatives make ECNP the largest non-institutional supporter of neuropsychopharmacological research and education in Europe.

The characteristics that have defined ECNP for 25 years—its focus on high-quality research and education; excellent organization; constructive, but independent engagement with industry; and close co-operation with national European and international organisations—continue to shape its strategic direction and guide its future.

For the last 25 years ECNP’s role in advancing the field has been critical; in the next 25 it will even be more so.
Governance and Policies

MISSION STATEMENT

The Executive Committee of ECNP has defined a mission statement which spells out its overall goals and primary objectives and provides a context in which the organisation’s strategies are formulated: “To advance the science of the brain, promote better treatment and enhance brain health”.

The policy plan, with the strategy for the coming years, can be found on: www.ecnp.eu.

ETHICAL CODE OF CONDUCT

Mutual responsibility, a higher threshold of standards, and closer adherence to a code of conduct were all getting increased attention. To face these challenges, ECNP has established an Ethical Code of Conduct [link], which will give a well balanced direction for ECNP and its members how to behave and handle their activities and practical matters in real life. The document clearly recognises the need to uphold the highest ethical standards in research and the important of animal welfare issues. The Code of Conduct also stresses the importance of transparency in both the scientific and clinical domains which is in line with EU directives.

Members of ECNP were given the opportunity to comment of the draft version of the Ethical Code of Conduct. At the General Assembly, held on 15 October 2012 in Vienna, Austria, the Ethical Code of Conduct was ratified by its members and put into use.

Allegations of violations of the Ethical Code of Conduct from any member will be reviewed by the President, Executive Director and the chair of the ECNP Review Board to determine whether the allegation is covered by the Code of Conduct. If the allegation is deemed to be so covered, the ECNP Review Board will consider written evidence from relevant parties and recommend to the Executive Committee whether expulsion should be considered or a lesser reaction such as a written warning.
The ECNP Review Board (previously called “Scientific Committee”) was established in 2007 with the broad aim of overseeing the quality assurance of ECNP’s governance and that of its activities. It advises the Executive Committee on the independence and procedural rigor of all ECNP projects and initiatives and monitors serious complaints concerning the College, ensuring an appropriate and timely response. In 2012 the rationale of the ECNP Review Board was made official by taking it up in the new ECNP Bylaws.

At the General Assembly, held on 15 October 2012 in Vienna, Austria, the new version of the Bylaws was ratified by its members and put into use.

The major changes in the new bylaws are:
- Inclusion of e-voting
- Introduction of the ECNP Review Board, a committee that helps strengthen the quality of the college
- The legal states of the Executive Director and the ECNP Office
- The Code of Ethics

The ECNP Review Board (ERB)

The ECNP Review Board (previously called “Scientific Committee”) was established in 2007, with the broad aim of overseeing the quality assurance of ECNP’s governance and that of its activities. It advises the Executive Committee on the independence and procedural rigor of all ECNP projects and initiatives and monitors serious complaints concerning the College, ensuring an appropriate and timely response. In 2012 the rationale of the ECNP Review Board was made official by taking it up in the new ECNP Bylaws.

The ERB ensures the ECNP organisation is
- Effective and focussed on its mission
- Serving the interests of the membership
- In a transparent, ethical and balanced way
- Monitoring its governance, activities & strategy
- Providing independent advice to Executive
- Responding to complaints and disagreements

ECNP Review Board
William Deakin, United Kingdom, chair
Laurence Lanfumey, France
Rafael Maldonado, Spain
Barbara Sahakian, United Kingdom
JUNIOR MEMBERS ADVISORY PANEL (J-MAP)

At the core of ECNP are a number of committees that are tasked with ensuring the college can effectively manage and best represent the needs of different members within its reach. With that in mind, the Junior Members Advisory Panel (J-MAP) has been assembled to make sure the college is responsive to the needs and wishes of its future members.

Comprised of a multinational team that includes graduates of the Workshop (to represent the pre-clinical multidisciplinary component) and the ECNP Schools, the panel will be rotated with fresh graduates on a regular basis to ensure that it can always remain very closely related to the needs of current juniors.

As chair of the panel, Florian Riese (Psychiatric University Hospital Zurich, Switzerland) shared the aims of J-MAP, as well as touching upon the general initiatives that ECNP has in place to ensure a better and more inclusive future for its junior members. By organising places to network that have a more accessible atmosphere, J-MAP hopes the junior members will feel more comfortable, and make more connections that will encourage them to return to subsequent meetings and other activities.

They also hope to create an ongoing communication platform so that people who, for example, attended the schools and workshops can continue or maintain their professional relations to the other participants. To actually have exposure to senior members is a unique opportunity.
ECNP Membership

Membership is the basis of the volunteer structure on which the College’s public-interest activities depend. Annually, volunteers give hundreds of thousands of hours of their time. Without this commitment, and the remarkable investment of time and energy that comes with it, ECNP could not function.

MEMBERSHIP NUMBERS

The total number of ECNP members increased in 2012. 105 Ordinary Members, 87 Associate Members and 7 Corresponding members joined the College, amounting to a total number of 1190 members. Seven members cancelled their membership.

FELLOW MEMBERSHIP

In 2012 the College introduced a new membership category: Fellow Members. ECNP Fellows are appointed by the Executive Committee, in recognition of scientific distinction and notable contributions to the College. The role of the Fellow is to be actively engaged in the College, by sitting on committees, participating in ECNP Networks, lecturing at ECNP Seminars, etc. In addition, Fellows also play an integral part in the ECNP Certificate Programme by acting as mentor for a Certificate student, assisting him/her in refining a suitable research topic, offering oversight in the execution of the project, advising in the preparation of the abstract and poster (for presentation at the ECNP Congress), and providing a point of contact at the congress. As a Certificate mentor, a Fellow should expect five to six contact points over the course of the two-year certificate cycle and a total time commitment of approximately 20 hours a year.

The following criteria are considered by the EC:

- Have attended at least three ECNP Congresses in the last five years
- Have presented at one ECNP Congress in the last ten years
- Be a reviewer in good standing for European Neuropsychopharmacology
- Have served on an ECNP Committee, or volunteered to serve
- Have been active in organising an ECNP event (Seminar, School, Mini-Symposium, etc.)
- Have supervised or mentored research projects before.

Membership Committee

Gitte M. Knudsen, Denmark, chair
Yechiel Levkovitz, Israel
Hamish McAllister-Williams, United Kingdom
Carmen Moreno, Spain
Edwin Zvartau, Russia
## ECNP’s Fellow Members

<table>
<thead>
<tr>
<th>Carlo Altamura</th>
<th>Siegfried Kasper</th>
<th>Georgio Racagni</th>
</tr>
</thead>
<tbody>
<tr>
<td>Celso Arango</td>
<td>Gitte M. Knudsen</td>
<td>Andreas Reif</td>
</tr>
<tr>
<td>Francesc Artigas</td>
<td>Laurence Lanfumey</td>
<td>Janusz Rybakowski</td>
</tr>
<tr>
<td>David Baldwin</td>
<td>Stephen Lawrie</td>
<td>Koen Schruers</td>
</tr>
<tr>
<td>Anton Bespalov</td>
<td>Klaus-Peter Lesch</td>
<td>Alessandro Serretti</td>
</tr>
<tr>
<td>Nicoletta Brunello</td>
<td>Michel Le Moal</td>
<td>David Slattery</td>
</tr>
<tr>
<td>Eero Castrén</td>
<td>Yechiel Levkovitz.</td>
<td>Dan J. Stein</td>
</tr>
<tr>
<td>Roberto Cavallaro</td>
<td>Astrid Linthorst</td>
<td>Alexandra Šulcová</td>
</tr>
<tr>
<td>Philip Cowen</td>
<td>Paul J. Lucassen</td>
<td>Per Svenningsson</td>
</tr>
<tr>
<td>Bill Deakin</td>
<td>Rafael Maldonado</td>
<td>Jari Tiihonen</td>
</tr>
<tr>
<td>Naomi Fineberg</td>
<td>Hamish McAllister-Williams</td>
<td>Wim van den Brink</td>
</tr>
<tr>
<td>Christine Gispen-de Wied</td>
<td>Andreas Meyer-Lindenberg</td>
<td>Nic J.A. van der Wee</td>
</tr>
<tr>
<td>Lucianne Groenink</td>
<td>Mark Millan</td>
<td>Eric Vermetten</td>
</tr>
<tr>
<td>Guy Goodwin</td>
<td>Luisa Minghetti</td>
<td>Eduard Vieta</td>
</tr>
<tr>
<td>Michel Hamon</td>
<td>Agneta Nordberg</td>
<td>Ove Wiborg.</td>
</tr>
<tr>
<td>Jaanus Harro</td>
<td>David Nutt</td>
<td>Hans-Ulrich Wittchen</td>
</tr>
<tr>
<td>Andreas Heinz</td>
<td>Sven Ove Ögren.</td>
<td>Gil Zalsman</td>
</tr>
<tr>
<td>Edith Holsboer-Trachsler</td>
<td>Stefano Pallanti</td>
<td>Joseph Zohar</td>
</tr>
<tr>
<td>Cyril Höschl</td>
<td>Daniela Parolaro</td>
<td>Edwin Zvartau</td>
</tr>
<tr>
<td>Martien Kas</td>
<td>Andrzej Pilc</td>
<td></td>
</tr>
</tbody>
</table>
REDUCED FEES FOR ASSOCIATE MEMBERS

In 2011 the College proposed to lower the membership fee for Associate Members from € 75 to € 50 and for Associate Members from countries with a developing economy (according to the World Bank list) from € 50 to € 15. The proposal was ratified at the General Assembly meeting in September 2011 in Paris, France and came into effect on 1 January 2012.

MEMBERSHIP FEES 2012

<table>
<thead>
<tr>
<th>Membership</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ordinary Members</td>
<td>€ 120</td>
</tr>
<tr>
<td>Ordinary Members CDE *</td>
<td>€ 75</td>
</tr>
<tr>
<td>Associate Members</td>
<td>€ 50</td>
</tr>
<tr>
<td>Associate Members CDE</td>
<td>€ 15</td>
</tr>
<tr>
<td>Corresponding Members</td>
<td>€ 120</td>
</tr>
<tr>
<td>Corresponding Members CDE</td>
<td>€ 75</td>
</tr>
<tr>
<td>Retired Members</td>
<td>€ 75</td>
</tr>
</tbody>
</table>

OTHER NEWS

Next to direct online credit card payments, as of 2012 members can print out their invoice and receipt online, and after the payment has been settled, their membership certificate.
ECNP’s Ambassadors

ECNP was founded 25 years ago not just to foster and promote neuropsychopharmacological research in Europe, but to foster and promote it across Europe. This has been the guiding principle behind, amongst others, our Regional meetings, our Seminars and our emphasis on recruiting participants for the ECNP Congresses, Workshops and Schools from all corners of the region. The result is now a strong and vibrant support base, not just in Western Europe, but Eastern and Southern Europe as well.

In 2012 ECNP has launched an Ambassador’s programme, to draw in countries even further afield, many of which lack the infrastructure to sustain a national society, and so have fallen outside the existing Advisory Board of National Societies programme. For every country in Europe we plan to appoint an ECNP Ambassador. This person, a senior neuropsychopharmacologist in his or her region, will help to coordinate seminars and mini-symposia, to nominate junior scientists for the ECNP Schools and encourage application for the ECNP Workshop, and act as representative and point of contact for ECNP in his or her home country. Each ambassador will serve a term of two years.

The first meeting of the ECNP Ambassadors took place on 9 February 2012 in Sofia, Bulgaria.

Ambassadors

Armen Melik-Pashayan, Armenia
Luchezar G. Hranov, Bulgaria
Miro Jakovljević, Croatia
Eka Chkonia, Georgia
Elmars Rancâns, Latvia
Robertas Bunevicius, Lithuania
Eugenia Sinita, Moldova
Joao Bessa, Portugal
Maria Ladea, Romania
Peter Morozov, Russian Federation
Gorica M. Djokic, Serbia
Rok Tavcar, Slovenia
Oguz Karamustafaloglu, Turkey
In March 2012, the Executive Committee initiated a programme to mobilise ECNP members to contribute to a ‘living’ internet lexicon on neuropsychopharmacology by means of short, up-to-date articles on key terms and concepts in the field, written by leading experts and providing general users with a high-quality, scientifically rigorous resource. The glossary will be hosted on the ECNP website, but also linked within the relevant Wikipedia articles and referenced in the External Links section.

Public Outreach

DEPNET AND DEMENTIA NET

To address the wider, public need for high-quality information, ECNP had launched patient websites on depression (DepNet.org) and dementia (Dementia.org). With DepNet already available in five European languages, and with more in the pipeline, the plan is to have most of Europe covered in the next couple of years. ECNP works in close cooperation with GAMIAN-Europe (Global Alliance of Mental Illness Advocacy Networks-Europe), a patient-driven pan-European organisation, which represents the interests of persons affected by mental illness and advocates for their rights. Its main objectives are: advocacy, information and education, anti-stigma and discrimination, patients’ rights, co-operation, partnerships and capacity building.

In August 2012 ECNP and GAMIAN signed a letter of intent about collaboration for the operation and management of patient-oriented websites. This cooperation is in line with the College’s intention to open a channel to the public, aimed at increasing the presence of disorders of the brain in the public dialogue. The two sites www.depnet.org and www.dementianet.org will be operated on a European level by a steering committee composed of the College and GAMIAN, with similarly composed working groups at national level.

ECNP GLOSSARY

In March 2012, the Executive Committee initiated a programme to mobilise ECNP members to contribute to a ‘living’ internet lexicon on neuropsychopharmacology by means of short, up-to-date articles on key terms and concepts in the field, written by leading experts and providing general users with a high-quality, scientifically rigorous resource. The glossary will be hosted on the ECNP website, but also linked within the relevant Wikipedia articles and referenced in the External Links section.
Public Outreach

MEDICINES CHEST

The Medicines Chest, an initiative led by David Nutt, was initiated in 2011 to help clinical researchers gain access to pharmacological compounds held but unused by pharmaceutical companies. Frequently, many potentially useful drugs are not exploited in clinical research for a variety of reasons: for example, they are poorly documented by companies in the event that their development is discontinued. In addition, clinical researchers are frequently unaware which agents are potentially available for research purposes, how to acquire such drugs, and the conditions under which they can be exploited.

ECNP hopes to help overcome such problems by acting as an intermediary between companies and researchers, and already several pharmaceutical companies have agreed to participate in this endeavour.

A list of drugs has been identified as useful research compounds and this list has been made available on the ECNP website [link]. This list is not exhaustive and ECNP would be pleased to hear of colleagues in the field which compounds would be worthwhile adding to the list.

CLINICAL DATABASE

In 2012 an ECNP Clinical Database has been launched to collect patient data and make them available to scientists working in the field.

David Nutt
Past-President ECNP
The ECNP Certificate is a new initiative that brings together all of the college’s junior researcher programmes into a Europe-wide qualification backed by ECNP. At its core, the ECNP Certificate serves as recognition of the efforts and commitment of junior researchers in the field of applied and translational neuroscience with each candidate requiring to demonstrate a level of knowledge and skills that includes the ability to undertake either an original research project or effectively disseminate knowledge on the science and treatment of disorders of the brain by writing a scientific literature review or by organising an educational event.

Underpinning each certificate is one-to-one mentoring by an ECNP Fellow – experienced, senior members of the college from a number of wide-ranging backgrounds and international locations that are available to share their expertise and guidance, as well as giving feedback. Unlike PhD or Master’s Thesis structures, mentors do not offer close supervision, and in fact it is preferred that they be located in a different country to their candidate, with quarterly (typically) catch-ups on the most substantive matters.

To be eligible for one of the 20 (approximately) certificate places in each rotation, candidates must have participated in at least one ECNP Workshop, School or Seminar, or attended another ECNP-affiliated course. Once this is complete, an ECNP Fellow is then chosen under the guidance of the Certificate committee, and the project can begin.

Typically spanning six to twelve months, the project should culminate in a piece of original work or meaningful contribution that both the mentor and the Certificate Committee deem to be fit for accreditation and exhibition in poster format at the ECNP Congress. Once all these steps have been completed, the certificate itself will be bestowed upon candidates within the Keynote Session of the congress.

Although still in its early stages, the ECNP Certificate programme has already attracted candidates. The big challenge now is to get the word out, and to get people signed up.

The ECNP Certificate comes with no registration or tuition cost, and while it does not contain a grant, candidates can work remotely from their mentors, negating the need to travel, and once they complete the project they will be given free registration to exhibit their work at the ECNP Congress.
The journal of ECNP, *European Neuropsychopharmacology*, provides a medium for the prompt publication of articles in the field of neuropsychopharmacology. Its scope encompasses clinical and basic research relevant to the effects of centrally acting agents in its broadest sense.

The journal's impact factor has risen in 2012 to 4.595 (from 4.406 in 2011). The rejection rate has increased over time what brings it to 63% in 2012. The aim is 75-80%. Just over half of all submitted papers come from Europe. The publication time remained more or less the same although the aim still is to reduce it. Online articles continue to appear within 5 weeks. An increase is seen in online usage by institutions and in article downloads. This year a Health Advance smartphone application for the journal was introduced. This app offers access to abstracts and the full text should be available later on.

Also the scientific community moves more and more to e-search and therefore it was decided in 2011 to head for a transition of the printed version of the journal to an e-version. This transition came into effect on 1 July 2012. However those who would like to continue receiving the hard copy, could indicate so. Next to the ‘green advantage’ it enabled the College to provide open excess of the journal to colleagues from Eastern Europe almost for free. The journal is an excellent scientific leader and open access might open a route to scientific progression.

**E-NEWS**

ECNP continued in 2012 with the monthly e-news messages, an effective way to keep you in touch with ECNP and its community. E-news reports the latest news on ECNP’s upcoming meetings, activities, new initiatives and developments as well as highlights from other organisations.
The President of ECNP, Joseph Zo-ihar, initiated in 2010 the “President’s Messages”, monthly updates on ECNP activities with the intention to create an open and productive dialogue with colleagues in the field. These messages continued in 2011 and 2012. The plan is in accordance with the aim to establish open more communication channels to the public, the plan for 2013 is to create a President’s blog, an online collaborative platform in which the public can submit their reactions on the President’s Messages and new ideas online.

**ECNP MATTERS**

*ECNP Matters* is published twice or three times a year for the purpose of informing the ECNP community about important activities within the organisation. *ECNP Matters* contains practical, meeting-related information such as calls for papers, upcoming deadlines and reports on past meetings, contributions to the newsletter come from directly within the community itself. These contributions range from articles written by distinguished scientists sharing their knowledge and experience, to up-and-coming young scientists with the potential to become prominent leaders in their field of expertise. In 2012 two issues of ECNP Matters were published.

**SOCIAL MEDIA**

Social media has completely revolutionised the way we communicate with each other. It can also enable the organisation in sharing information in an informal, immediate and interactive way. Although social media can be intimidating for some, especially those with limited time and resources, its benefits outweigh the effort required. Therefore the College decided to step up its own social media activity, particularly on Facebook, Twitter and YouTube. You can ‘like’ ECNP at www.facebook.com/myECNP, www.twitter.com/myECNP and www.youtube.com/myECNP.
In an effort to bring high-quality information and insights about the brain and brain disorders to the informed and interested members of the public, ECNP has launched a new initiative called the 'Talk of the Month'. The 'Talk of the Month' is held in the form of a short video cast designed to summarise the key indications and developments in our field. Each invited speaker is an outstanding scientist in their specialised area of expertise and experienced in translating the science of neuropsychopharmacology into more general terms. The “Talk of the Month” videos are published on YouTube and the ECNP Website.

Talks recorded in 2012

<table>
<thead>
<tr>
<th>Name</th>
<th>Topic</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick McGorry</td>
<td>Early intervention and youth mental health</td>
<td>01 February 2012</td>
</tr>
<tr>
<td>René Kahn</td>
<td>Schizophrenia</td>
<td>01 March 2012</td>
</tr>
<tr>
<td>Robin Jacoby</td>
<td>Major depression in old age</td>
<td>01 April 2012</td>
</tr>
<tr>
<td>Trevor W. Robbins</td>
<td>Neuropsychopharmacology: bridging animal and human studies</td>
<td>01 May 2012</td>
</tr>
<tr>
<td>Andreas Meyer-Lindenburg</td>
<td>review of meta-analyses</td>
<td>01 June 2012</td>
</tr>
<tr>
<td>Richard Keefe</td>
<td>Cognitive impairment in schizophrenia</td>
<td>01 October 2012</td>
</tr>
<tr>
<td>Stefan Leucht</td>
<td>Neural mechanisms of risk for psychiatric disorders</td>
<td>01 November 2012</td>
</tr>
<tr>
<td>Til Wykes</td>
<td>Cognitive remediation and cognitive enhancement in schizophrenia</td>
<td>01 December 2012</td>
</tr>
</tbody>
</table>
Awards

ECNP LIFETIME ACHIEVEMENT AWARD

The ECNP Lifetime Achievement Award was established to recognise individuals who have made career-long and lasting contributions to the field of neuropsychopharmacology, at a national or international level. The award is presented biennially and specifically recognised a lifelong dedication to and a significant impact on the field of neuropsychopharmacology. The award winner receives an unrestricted grant of EUR 20,000 and a commemorative gift.

WINNER 2012

In 2012 the ECNP Lifetime Achievement Award was granted to Jules Angst, Emeritus Professor of Psychiatry at the University of Zurich (Switzerland) and Honorary Doctor of Heidelberg University, Germany. Jules Angst graduated in medicine from the University of Zurich in 1952 and trained in psychiatry under Manfred Bleuler at the Zurich University Psychiatric Hospital (the Burghölzli). In 1969 he was appointed Professor of Clinical Psychiatry and Director of the Burghölzli’s newly-founded Research Department, retiring in 1994. He remains active full time in epidemiological and clinical research.
ECNP NEUROPSYCHOPHARMACOLOGY AWARD

The ECNP Neuropsychopharmacology Award recognises innovative and distinguished research achievements in neuropsychopharmacology and closely related disciplines. The award is granted each year, alternating between basic science and clinical research. The award winner receives an unrestricted prize of EUR 20,000, a commemorative gift, and is invited to present the award plenary lecture at the ECNP Congress. In addition, the award winner is asked to submit a review article for publication in *European Neuropsychopharmacology* (to be submitted within six months after the award is granted).

In 2012 the ECNP Neuropsychopharmacology Award had a joint-recipient: Paul Harrison of the Department of Psychiatry of the University of Oxford, United Kingdom and Andreas Meyer-Lindenberg of the Central Institute of Mental Health, Mannheim, Germany.

WINNER 2012—PAUL HARRISON

Professor Harrison has headed a research group investigating molecular, neuropathological, psychopharmacological and genetic aspects of psychosis. The group had a particular current interest in the neurobiology of schizophrenia risk genes, and utilised a range of experimental platforms and methods to investigate this question. He has published about 250 papers, several books and also has clinical, teaching and administrative roles. His clinical work centres on treatment-resistant mood disorder and psychosis. He is a Deputy Editor for *Biological Psychiatry*, has served on various funding committees and chaired an NHS Research Ethics Committee. He has supervised 18 PhDs, and has been rated top lecturer on the Oxford psychiatry course for several years. He is currently President Elect of the British Association for Psychopharmacology.
ECNP MEDIA AWARD

In 2012 ECNP launched the ‘ECNP Media Award’, an award created in recognition of major contributions to destigmatising disorders of the brain in any medium, like journalism, literature, dance, film or theatre. The objective of this award is to inform and educate the European public about the personal and social impact of disorders of the brain. The award may be given for a specific product or project published, broadcast or posted online within Europe, in any European language. The winner of the first ECNP Media Award was the Science Media Centre based in London, United Kingdom. The Science Media Centre is a model for how science can inform the public, facilitate public debate and enrich policy-making. Through its media relations activities, and especially its highly influential news briefings, the Centre has been extremely successful in spreading the knowledge and ensuring that science is made real and relevant for millions of people. The Science Media Centre manages to ‘translate’ the extraordinary advances being made every day in scientific research to the public in a direct and tangible way. The Science and Media Centre has made significant contributions to destigmatising disorders of the brain.

WINNER 2012— ANDREAS MEYER-LINDENBERG

Prof. Dr. Meyer-Lindenberg is Director of the Central Institute of Mental Health, as well as the Medical Director of the Department of Psychiatry and Psychotherapy at the Institute, based in Mannheim, Germany and Professor and Chairman of Psychiatry and Psychotherapy at the University of Heidelberg in Heidelberg, Germany, and he is board certified in psychiatry, psychotherapy, and neurology. Prof. Dr. Meyer-Lindenberg is on the editorial board of a number of journals, such as Nature, Biological Psychiatry, Psychiatry Research: Neuroimaging, and Neuroimage, and a reviewer for many others, including Journal of Neuroscience, Molecular Psychiatry, Nature Medicine, Nature Reviews Neuroscience, Neuroimage, Neuroscience, and Neuropsychologia. He is also the author of more than 200 peer-reviewed articles and book chapters. His research interests focus on using multimodal neuroimaging approaches to characterize functional brain circuits underlying the genetic risk for psychiatric disorders and cognitive dysfunction.
EXECUTIVE COMMITTEE

Officers
Joseph Zohar, Israel, **president**
Hans-Ulrich Wittchen, Germany, **vice-president**
Guy Goodwin, United Kingdom, **president-elect**
David Nutt, United Kingdom, **past-president**
Sven Ove Ögren, Sweden, **secretary**
Nicoletta Brunello, Italy, **treasurer**

Chair Scientific Programme Committee
Wim van den Brink, The Netherlands

Editor-in-Chief European Neuropsychopharmacology
Michael Davidson, Israel

Executive Director
Alexander Schubert, The Netherlands

Councillors
Celso Arango, Spain
Jaanus Harro, Estonia
Gitte M. Knudsen, Denmark
Mark J. Millan, France
Wim van den Brink, The Netherlands
Eduard Vieta, Spain
INDEPENDENT COMMITTEES

**Scientific Programme Committee**

25th ECNP Congress

Wim van den Brink, The Netherlands, *chair*
Celso Arango, Spain, *chair* Educational Committee
Michael Davidson, *Israel, editor-in-chief* journal *ENP*
Eero Castrén, Finland
Damiaan Denys, The Netherlands
Antonio Gil-Nagel, Spain
Michel Hamon, France
Michal Hrdlicka, Czech Republic
Zoltán Janka, Hungary
Hans Lassmann, Austria
Astrid Linthorst, United Kingdom
Andreas Meyer-Lindenberg, Germany
Wolfgang Oertel, Germany
Isabella Pacchiarotti, Spain
Marie-Claude Potier, France
Rainer Rupprecht, Germany
Joanna Strosznajder, Poland
Louk Vanderschuren, The Netherlands

**Nominating Committee**

David Nutt, United Kingdom, *chair*
Guy Goodwin, United Kingdom
Cyril Höschl, Czech Republic
Marian Joëls, The Netherlands
Laurence Lanfumey, France
Sven Ove Ögren, Sweden
Joseph Zohar, Israel

**ECNP Review Board**

William Deakin, United Kingdom, *chair*
Laurence Lanfumey, France
Rafael Maldonado, Spain
Barbara Sahakian, United Kingdom
ECNP Committees

**Award Committee**
Julien Mendlewicz, Belgium, *chair*
Kaj Blennow, Sweden
Philip J. Cowen, United Kingdom
Guy Goodwin, United Kingdom
Andreas Heinz, Germany
Michel Le Moal, France
Georgio Racagni, Italy
Jari Tiihonen, Finland

**Communication Committee**
Hans-Ulrich Wittchen, Germany, *chair*
Guy Goodwin, United Kingdom
Jaanus Harro, Estonia
Michel Hamon, France
David Nutt, United Kingdom
Joseph Zohar, Israel

Advisor:
Michael Davidson, Israel

**Certificate Committee**
Celso Arango, Spain
Naomi Fineberg, United Kingdom
Koen Schruers, The Netherlands
Alexander Schubert, The Netherlands
Joseph Zohar, Israel

**Consultation Committee**
David Nutt, United Kingdom, *chair*
Celso Arango, Spain
David Baldwin, United Kingdom
Karl Broich, Germany
Christine C. Gispen-de Wied, The Netherlands
Guy Goodwin, United Kingdom
Maria Isaac, United Kingdom
Jim van Os, The Netherlands
Sven Ove Ögren, Sweden

Co-opt
Michael Davidson, Israel

**Educationhal Committee**
Celso Arango, Spain, *chair*
Naomi Fineberg, United Kingdom
Edith Holsboer-Trachsler, Switzerland
Stefano Pallanti, Italy
Walter Pirker, Austria
Florian Riese, Switzerland
Janusz H. Rybakowski, Poland
Koen Schruers, The Netherlands
Gil Zalsman, Israel
Joseph Zohar, Israel
**Junior Members Advisory Panel**

Florian Riese, Switzerland, chair  
Covadonga M. Díaz-Caneja, Spain  
Kfir Feffer, Israel  
Rajna Knez, Croatia  
Kara Panetta, United Kingdom  
Olga Paravaya, Belarus

**Membership Committee**

Gitte M. Knudsen, Denmark, *chair*  
Yechiel Levkovitz, Israel  
Hamish McAllister-Williams, United Kingdom  
Carmen Moreno, Spain  
Edwin Zvartau, Russia

**Workshop Committee**

Mark J. Millan, France, *chair*  
Michel Hamon, France  
Jaanus Harro, Estonia  
Martien Kas, The Netherlands  
Astrid Linthorst, United Kingdom  
Andreas Meyer-Lindenberg, Germany  
Andreas Reif, Germany  
Alessandro Serretti, Italy  
David A. Slattery, Germany  
Per Svenningsson, Sweden  
Eduard Vieta, Spain

**School Committee**

Guy Goodwin, United Kingdom, *chair*  
Celso Arango, Spain  
Robin Jacoby, United Kingdom  
Joseph Zohar, Israel  
Alessandro Zuddas, Italy
Addiction
Julio Bobes, Spain
Jocelyne Caboche, France
Karen Ersche, United Kingdom
Gabriele Fischer, Austria
Johan Franck, Sweden
Philip Gorwood, France
Anne Lingford-Hughes, United Kingdom
Marcus Munafò, United Kingdom
Florence Noble, France
Rainer Spanagel, Germany
Martien Kas, The Netherlands
Klaus-Peter Lesch, Germany
Isabelle Mansuy, Switzerland
Oscar Marin, Spain
Anabel Martinez-Aran, Spain
Jean Luc Martinot, France
Inga Neumann, Germany
Nick Ramsey, The Netherlands
Oliver Stiedl, The Netherlands
Anxiety disorders, OCD, stress related disorders and treatment
David Baldwin, United Kingdom
Johan A. den Boer, The Netherlands
Damiaan Denys, The Netherlands
Dave Finn, Ireland
Andrew Gloster, Germany
Astrid Linthorst, United Kingdom
Raymond Mongeau, France
Stefano Pallanti, Italy
Jan Buitelaar, The Netherlands
Josefina Castro-Fornieles, Spain
Michal Hrdlicka, Czech Republic
Rainald Mössner, Germany
Mara Parelloada, Spain
Marie-Claude Potier, France
Abraham Weizman, Israel
Alessandro Zuddas, Italy
Child and adolescent disorders treatment
Jan Buitelaar, The Netherlands
Josefina Castro-Fornieles, Spain
Rainald Mössner, Germany
Mara Parelloada, Spain
Marie-Claude Potier, France
Abraham Weizman, Israel
Alessandro Zuddas, Italy
Dementia and neurological disorders
Christoph Baumgartner, Austria
Jan Booj, The Netherlands
Christoph Hock, Switzerland
Hans Lassmann, Austria
Jean Mariani, France
Walter Pirker, Austria
Juha Rinne, Finland
Frederic Saudou, France
Michael Schüpbach, Switzerland
Mood disorders and treatment
Ian Anderson, United Kingdom
Catherine Belzung, France
Francesc Colom, Spain
Catherine Harmer, United Kingdom
Erkki Isometsä, Finland
Marion Leboyer, France
Arne Mørk, Denmark
Mariusz Papp, Poland
Rainer Rupprecht, Germany
Alessandro Serretti, Italy
Daniel Souery, Belgium
Per Svenningsson, Sweden
Aysegül Yildiz, Turkey
Psychotic disorders and treatment
Istvan Bitter, Hungary
Ronan Depoortere, France
Filippo Drago, Italy
Liewe de Haan, The Netherlands
Andreas Meyer-Lindenber, Germany
Paula Moran, United Kingdom
Dieter Naber, Germany
Joseph Peuskens, Belgium
Dan Rujescu, Germany
Janusz Rybakowski, Poland
John Waddington, Ireland
Basic and clinical neuroscience
Anton Bespalov, Germany
Eero Castrén, Finland
Kevin Fone, United Kingdom
Andreas Heinz, Germany

ECNP committees

SCIENTIFIC ADVISORY PANELS
Finance

REIMBURSEMENT COMMITTEE MEMBERS

**Secretarial Assistance**
The President of the Executive Committee receives €15,000 for secretarial assistance.

The past-president, president-elect, vice-president, secretary and treasurer all receive €4,000 for secretarial assistance.

**Reimbursement small expenses**
All members of the Executive Committee receive a yearly reimbursement of €1,500. This amount should cover their expenses for ground transportation, lunch, dinner, drinks etc.

The members of the Executive Committee receive the reimbursements as stated above and do not receive any remuneration for their services.
## Finance

### BALANCE SHEET AS AT 31 DECEMBER 2012 (2011)

<table>
<thead>
<tr>
<th></th>
<th>31-12-2012 CHF</th>
<th>31-12-2012 €</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CURRENT ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts receivable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Debtors</td>
<td>10.711</td>
<td>8.878</td>
</tr>
<tr>
<td>Amounts owed by foundation Stichting Buro ECNP</td>
<td>952.340</td>
<td>789.341</td>
</tr>
<tr>
<td>Amounts owed by ECNP Research and Scholarship Foundation</td>
<td>2.197.459</td>
<td>1.821.350</td>
</tr>
<tr>
<td>Taxes</td>
<td>374.649</td>
<td>310.526</td>
</tr>
<tr>
<td>Other accounts receivable</td>
<td>504.217</td>
<td>417.917</td>
</tr>
<tr>
<td></td>
<td><strong>4.039.376</strong></td>
<td><strong>3.348.012</strong></td>
</tr>
<tr>
<td>Securities</td>
<td>13.485.300</td>
<td>11.177.205</td>
</tr>
<tr>
<td>Bank deposits</td>
<td>81.115</td>
<td>67.232</td>
</tr>
<tr>
<td></td>
<td><strong>17.605.791</strong></td>
<td><strong>14.592.449</strong></td>
</tr>
</tbody>
</table>
# Finance

**BALANCE SHEET AS AT 31 DECEMBER 2012 (2011)**

<table>
<thead>
<tr>
<th></th>
<th>31-12-2012</th>
<th>31-12-2012</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CHF</td>
<td>€</td>
</tr>
<tr>
<td><strong>LIABILITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Equity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brought forward from last year</td>
<td>16,376,502</td>
<td>13,573,560</td>
</tr>
<tr>
<td>Result 2012 (2011)</td>
<td>1,084,023</td>
<td>898,484</td>
</tr>
<tr>
<td></td>
<td>17,460,525</td>
<td>14,472,044</td>
</tr>
<tr>
<td>Current liabilities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trade creditors</td>
<td>10,548</td>
<td>8,743</td>
</tr>
<tr>
<td>Other liabilities</td>
<td>134,719</td>
<td>111,662</td>
</tr>
<tr>
<td></td>
<td>145,267</td>
<td>120,405</td>
</tr>
<tr>
<td></td>
<td><strong>17,605,792</strong></td>
<td><strong>14,592,449</strong></td>
</tr>
</tbody>
</table>
## Finance

### Profit and Loss Account 2012 (2011)

<table>
<thead>
<tr>
<th></th>
<th>2012 (CHF)</th>
<th>2012 (€)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Income</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Membership fees</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Personal membership fees</td>
<td>116,970</td>
<td>96,950</td>
</tr>
<tr>
<td>Donations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unrestricted grant</td>
<td>447,209</td>
<td>370,666</td>
</tr>
<tr>
<td>Interest and similar income</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Royalties Elsevier</td>
<td>57,848</td>
<td>47,947</td>
</tr>
<tr>
<td>Interest bank</td>
<td>14,850</td>
<td>12,308</td>
</tr>
<tr>
<td>Interest on bonds</td>
<td>248,531</td>
<td>205,993</td>
</tr>
<tr>
<td>Dividend on shares</td>
<td>58,941</td>
<td>48,853</td>
</tr>
<tr>
<td>Adjustment shares and bonds to market value</td>
<td>(35,909)</td>
<td>(29,763)</td>
</tr>
<tr>
<td>Realized results on securities</td>
<td>905,251</td>
<td>750,312</td>
</tr>
<tr>
<td><strong>Total Income (balance forward)</strong></td>
<td>1,249,512</td>
<td>1,035,650</td>
</tr>
</tbody>
</table>

TOTAL INCOME (balance forward) 1,813,691 1,503,266
## Finance

<table>
<thead>
<tr>
<th></th>
<th>2012 (CHF)</th>
<th>2012 (€)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TOTAL INCOME (balance forward)</strong></td>
<td>1,813,691</td>
<td>1,503,266</td>
</tr>
<tr>
<td><strong>EXPENSES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Administration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recharge by Stichting Buro ECNP</td>
<td>199,206</td>
<td>165,111</td>
</tr>
<tr>
<td><strong>Other expenses</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Audit fee and consulting charges</td>
<td>121,295</td>
<td>100,535</td>
</tr>
<tr>
<td>Meeting and travel expenses</td>
<td>112,547</td>
<td>93,284</td>
</tr>
<tr>
<td>Secretarial support EC-officers</td>
<td>65,151</td>
<td>54,000</td>
</tr>
<tr>
<td>Provision bad debt</td>
<td>7,299</td>
<td>6,050</td>
</tr>
<tr>
<td>Membership fees to other organisations</td>
<td>31,383</td>
<td>26,012</td>
</tr>
<tr>
<td>25-years ECNP</td>
<td>33,716</td>
<td>27,945</td>
</tr>
<tr>
<td>General college expenses</td>
<td>6,914</td>
<td>5,731</td>
</tr>
<tr>
<td><strong>Subtotal</strong></td>
<td>378,305</td>
<td>313,557</td>
</tr>
<tr>
<td><strong>Publication</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>European Neuropsychopharmacology</td>
<td>80,102</td>
<td>66,392</td>
</tr>
<tr>
<td>ECNP Matters</td>
<td>6,043</td>
<td>5,009</td>
</tr>
<tr>
<td>Depression Net</td>
<td>23,476</td>
<td>19,458</td>
</tr>
<tr>
<td>ECNP Certificate</td>
<td>11,739</td>
<td>9,730</td>
</tr>
<tr>
<td>E-News</td>
<td>8,962</td>
<td>7,428</td>
</tr>
<tr>
<td>Talk of the Month</td>
<td>4,703</td>
<td>3,898</td>
</tr>
<tr>
<td>Wikipedia</td>
<td>5,429</td>
<td>4,500</td>
</tr>
<tr>
<td>Material</td>
<td>6,752</td>
<td>5,596</td>
</tr>
<tr>
<td><strong>TOTAL EXPENSES (balance forward)</strong></td>
<td>724,717</td>
<td>600,679</td>
</tr>
<tr>
<td></td>
<td>2012</td>
<td>2012</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>--------</td>
<td>--------</td>
</tr>
<tr>
<td></td>
<td>CHF</td>
<td>€</td>
</tr>
<tr>
<td><strong>TOTAL EXPENSES (balance forward)</strong></td>
<td>724.717</td>
<td>600.679</td>
</tr>
<tr>
<td>Interest and similar charges</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Account commission costs</td>
<td>1.926</td>
<td>1.596</td>
</tr>
<tr>
<td>Bank charges</td>
<td>3.025</td>
<td>2.507</td>
</tr>
<tr>
<td>Subtotal</td>
<td>4.951</td>
<td>4.103</td>
</tr>
<tr>
<td><strong>TOTAL EXPENSES</strong></td>
<td>729.668</td>
<td>604.782</td>
</tr>
<tr>
<td><strong>NET RESULT</strong></td>
<td>1,084.023</td>
<td>898.484</td>
</tr>
</tbody>
</table>
### 3.4 EXPLANATORY NOTES TO THE BALANCE SHEET AS AT 31 DECEMBER 2012 (2011)

<table>
<thead>
<tr>
<th></th>
<th>31-12-2012</th>
<th>31-12-2011</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CHF</td>
<td>€</td>
</tr>
<tr>
<td><strong>CURRENT ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts receivable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Debtors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Personal membership fees</td>
<td>28,013</td>
<td>23,219</td>
</tr>
<tr>
<td>Less: Provision for bad debtors</td>
<td>(17,302)</td>
<td>(14,341)</td>
</tr>
<tr>
<td></td>
<td>10,711</td>
<td>8,878</td>
</tr>
<tr>
<td>Taxes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corporate income tax 2009</td>
<td>344,868</td>
<td>285,842</td>
</tr>
<tr>
<td>Value added tax</td>
<td>29,781</td>
<td>24,684</td>
</tr>
<tr>
<td></td>
<td>374,649</td>
<td>310,526</td>
</tr>
<tr>
<td>Other accounts receivable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unrestricted grant to be received</td>
<td>301,625</td>
<td>250,000</td>
</tr>
<tr>
<td>Reimbursement receivable</td>
<td>57,848</td>
<td>47,947</td>
</tr>
<tr>
<td>Dividend shares receivable</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Interest bank-savings</td>
<td>157</td>
<td>130</td>
</tr>
<tr>
<td>Interest bonds</td>
<td>144,587</td>
<td>119,840</td>
</tr>
<tr>
<td></td>
<td>504,217</td>
<td>417,917</td>
</tr>
</tbody>
</table>
## Finance

### Securities

<table>
<thead>
<tr>
<th></th>
<th>31-12-2012 (CHF)</th>
<th>31-12-2011 (€)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bonds</td>
<td>8,506,679</td>
<td>7,050,706</td>
</tr>
<tr>
<td>Shares</td>
<td>4,978,621</td>
<td>4,126,499</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>13,485,300</strong></td>
<td><strong>11,177,205</strong></td>
</tr>
</tbody>
</table>

As per 31 December 2012 the market value of the shares and bonds amounts € 11,295,744

For further specification of securities we refer to annex 4.1 of this report.

### Bank deposits

<table>
<thead>
<tr>
<th>Deposit Type</th>
<th>31-12-2012 (CHF)</th>
<th>31-12-2011 (€)</th>
</tr>
</thead>
<tbody>
<tr>
<td>F. van Lanschot Bankiers, current-account</td>
<td>43,480</td>
<td>36,038</td>
</tr>
<tr>
<td>F. van Lanschot Bankiers, deposit</td>
<td>3,881</td>
<td>3,217</td>
</tr>
<tr>
<td>ING Bank N.V., deposit</td>
<td>33,666</td>
<td>27,904</td>
</tr>
<tr>
<td>ING Bank N.V., deposit</td>
<td>60</td>
<td>50</td>
</tr>
<tr>
<td>ING Bank N.V., current account</td>
<td>28</td>
<td>23</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>81,115</strong></td>
<td><strong>67,232</strong></td>
</tr>
</tbody>
</table>

### Current liabilities

### Other liabilities

<table>
<thead>
<tr>
<th>Liability</th>
<th>31-12-2012 (CHF)</th>
<th>31-12-2011 (€)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Legal advice</td>
<td>60,718</td>
<td>50,326</td>
</tr>
<tr>
<td>Recharge costs Stichting Buro ECNP</td>
<td>59,339</td>
<td>49,183</td>
</tr>
<tr>
<td>Accrued audit fee</td>
<td>8,023</td>
<td>6,650</td>
</tr>
<tr>
<td>Bank charges</td>
<td>72</td>
<td>60</td>
</tr>
<tr>
<td>Other liabilities</td>
<td>6,567</td>
<td>5,443</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>134,719</strong></td>
<td><strong>111,662</strong></td>
</tr>
</tbody>
</table>
**General Information**

The European College of Neuropsychopharmacology (ECNP) is a public-interest-serving entity.

Address:

European College of Neuropsychopharmacology
Bolognalaan 28
3584 CJ Utrecht
Tel: 0031 88 7569555
E-mail: secretariat@ecnp.eu  Website: www.ecnp.eu

RSIN: 823523974